Taysha Gene Therapies price to sales ratio TSHA

Market value divided by revenue over the last twelve months, since 2024.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 186×; May 2026
3-year median: 43.3×
3-year range: 23.9× to 198×
Peer median: 7.1×

Taysha Gene Therapies' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in May 2026, at 186×.

On the days it had one over the last 3 years, its median was 43.3×, from 23.9× in Nov 2024 to 198× in Mar 2026.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	186×	120×	198×
2025	182×	30.0×	182×
2024	36.2×	23.9×	67.0×

Against its peers

Companies in Biotechnology nearest Taysha Gene Therapies' size, closest first, today.

Company	Price to sales ratio
TSHATaysha Gene Therapies	n/m
MGTXMeiraGTx	2.2×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
PLXProtalix BioTherapeutics	2.5×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
Peer median	7.1×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Taysha Gene Therapies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.